Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

The aim of this study is to evaluate usual care versus biomarker-directed care (using blood eosinophil counts) for the management of asthma patients in primary care setting. The study hypothesizes that BEC is a valuable biomarker that can guide asthma treatment, and result in reduction in asthma exacerbations, better symptom control and improvement in quality of life compared to usual arm in mild to moderate asthma patients in the primary care setting. Researchers would compare using blood eosinophil count guided to usual care to see if biomarker-directed asthma treatment and management

NCT Number	NCT07486401
Lead Sponsor	National Healthcare Group Polyclinics Collaborators: National Medical Research Council (NMRC), Singapore, Singapore General Hospital
Conditions	Asthma Exacerbations, Biomarkers / Blood, Eosinophil Blood Count
Enrollment	240 participants
Start Date	2025-12-03
Primary Completion	2028-12-31 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-20